Literature DB >> 28924814

The prognostic value of heart rate response during vasodilator stress myocardial perfusion imaging in patients with end-stage renal disease undergoing renal transplantation.

Wael AlJaroudi1, Chiedozie Anokwute2, Ibtihaj Fughhi2, Tania Campagnoli3, Marwan Wassouf4, Aviral Vij3, Michael Kharouta2, Andrew Appis2, Amjad Ali5, Rami Doukky6,7,8.   

Abstract

BACKGROUND: In asymptomatic end-stage renal disease (ESRD) patients undergoing vasodilator stress myocardial perfusion imaging (MPI) prior to renal transplantation (RT), the impact of pre-transplant heart rate response (HRR) to vasodilator stress on post-RT outcomes is unknown.
METHODS: We analyzed a retrospective cohort of asymptomatic patients with ESRD who underwent a vasodilator stress SPECT-MPI and subsequently received RT. Blunted HRR was defined as HRR <28% for regadenoson stress and <20% for adenosine stress. The primary endpoint was major adverse cardiac events (MACE), defined as cardiac death or myocardial infarction. Clinical risk was assessed using the sum of risk factors set forth by the AHA/ACCF consensus statement on the assessment of RT candidates.
RESULTS: Among 352 subjects, 140 had an abnormal pre-transplant HRR. During a mean follow-up of 3.2 ± 2.0 years, 85 (24%) MACEs were observed. Blunted HRR was associated with increased MACE risk (hazard ratio 1.72; 95% confidence interval 1.12-2.63, P = 0.013), and remained significant after adjustment for gender, sum of AHA/ACCF risk factors, summed stress score, baseline heart rate, and β-blocker use. HRR was predictive of MACE in patients with normal MPI and irrespective of clinical risk. Blunted HRR was associated with a significant increase in post-operative (30-day) MACE risk (17.9% vs 8.5%; P = 0.009).
CONCLUSION: In asymptomatic ESRD patients being evaluated for RT, a blunted pre-transplant HRR was predictive of post-RT MACE. HRR may be a valuable tool in the risk assessment of RT candidates.

Entities:  

Keywords:  Heart rate response; adenosine; end-stage renal disease; myocardial perfusion imaging; prognosis; regadenoson; transplant

Year:  2017        PMID: 28924814     DOI: 10.1007/s12350-017-1061-2

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  24 in total

Review 1.  Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation.

Authors:  Krista L Lentine; Salvatore P Costa; Matthew R Weir; John F Robb; Lee A Fleisher; Bertram L Kasiske; Robert L Carithers; Michael Ragosta; Kline Bolton; Andrew D Auerbach; Kim A Eagle
Journal:  J Am Coll Cardiol       Date:  2012-07-02       Impact factor: 24.094

2.  Multimodality Imaging for CAD Detection Before Renal Transplantation.

Authors:  Fadi G Hage; Ami E Iskandrian
Journal:  JACC Cardiovasc Imaging       Date:  2015-05

3.  Value of myocardial perfusion imaging in renal transplant evaluation.

Authors:  Chong Ghee Chew; Steve Unger; Sepehr Shakib
Journal:  Nephrology (Carlton)       Date:  2013-05       Impact factor: 2.506

4.  Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.

Authors:  Wael AlJaroudi; Tania Campagnoli; Ibtihaj Fughhi; Marwan Wassouf; Amjad Ali; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2015-08-22       Impact factor: 5.952

5.  Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome.

Authors:  Fadi G Hage; Gilbert Perry; Jaekyeong Heo; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2010-03-15       Impact factor: 2.778

6.  Validation of a clinical pathway to assess asymptomatic renal transplant candidates using myocardial perfusion imaging.

Authors:  Rami Doukky; Ibtihaj Fughhi; Tania Campagnoli; Marwan Wassouf; Michael Kharouta; Aviral Vij; Chiedozie Anokwute; Andrew Appis; Amjad Ali
Journal:  J Nucl Cardiol       Date:  2017-05-08       Impact factor: 5.952

7.  Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease.

Authors:  Yasmeen Golzar; Rami Doukky
Journal:  Curr Cardiovasc Imaging Rep       Date:  2017-03-18

8.  A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging.

Authors:  Fadi G Hage; Phillip Dean; Fahad Iqbal; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2011-07-22       Impact factor: 5.952

Review 9.  The scope of coronary heart disease in patients with chronic kidney disease.

Authors:  Fadi G Hage; Rajesh Venkataraman; Gilbert J Zoghbi; Gilbert J Perry; Angelo M DeMattos; Ami E Iskandrian
Journal:  J Am Coll Cardiol       Date:  2009-06-09       Impact factor: 24.094

10.  Role of myocardial perfusion imaging in patients with end-stage renal disease undergoing coronary angiography.

Authors:  Rajesh Venkataraman; Fadi G Hage; Todd Dorfman; Jaekyeong Heo; Raed A Aqel; Angelo M de Mattos; Ami E Iskandrian
Journal:  Am J Cardiol       Date:  2008-09-11       Impact factor: 2.778

View more
  4 in total

1.  Risk stratification for renal transplantation: A role for heart rate response?

Authors:  Matthew Topel; Leslee J Shaw; Joe X Xie
Journal:  J Nucl Cardiol       Date:  2017-10-30       Impact factor: 5.952

2.  The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging.

Authors:  Muhammad Shahzeb Khan; Abdul Wahab Arif; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2020-10-08       Impact factor: 5.952

Review 3.  Cardiac imaging for the assessment of patients being evaluated for kidney transplantation.

Authors:  Kameel Kassab; Rami Doukky
Journal:  J Nucl Cardiol       Date:  2021-03-05       Impact factor: 5.952

Review 4.  Cardiac evaluation of the kidney or liver transplant candidate.

Authors:  Paul Emile Levy; Sadiya S Khan; Lisa B VanWagner
Journal:  Curr Opin Organ Transplant       Date:  2021-02-01       Impact factor: 2.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.